Pacira | PCRX - Equity Capital And Reserves


Pacira reported $653.89M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Assertio Holdings USD 105.8M 12.5M Sep/2025
Astellas Pharma JPY 1.83T 65.92B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
J&J USD 81.19B 358M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026
Xoma USD 87.94M 15.5M Sep/2025
Zoetis USD 3.23B 98M Mar/2026